




RealRate

# PHARMACEUTICAL 2021

## Benitec Biopharma Inc. Rank 154 of 402





RealRate

# PHARMACEUTICAL 2021

## Benitec Biopharma Inc. Rank 154 of 402



The relative strengths and weaknesses of Benitec Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Benitec Biopharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Benitec Biopharma Inc. is the variable Net Income, reducing the Economic Capital Ratio by 59% points.

The company's Economic Capital Ratio, given in the ranking table, is 144%, being 96% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	10,809
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,136
Liabilities, Non-Current	213
Other Assets	404
Other Compr. Net Income	-89
Other Expenses	-185
Other Liabilities	0
Other Net Income	7.0
Other Revenues	102
Property and Equipment	374
Research and Development	3,001
Selling, General and Administrative Expense	5,567

Output Variable	Value in 1000 USD
Assets	11,587
Liabilities	1,349
Expenses	8,383
Revenues	102
Stockholders Equity	10,238
Net Income	-8,274
Comprehensive Net Income	-8,318
Economic Capital Ratio	144%